Ardelyx draws $50M Term F loan to fund kidney-drug growth
What's the deal? Ardelyx has drawn a $50 million Term F loan, according to an SEC filing dated June 29, 2026. The non-revolving facility carries a fixed amortization schedule and is earmarked for general corporate purposes.
Why now? The draw activates capital Ardelyx had already lined up. In June 2025, it executed a Fifth Amendment to its 2022 loan agreement, immediately taking a $50 million Term E loan and securing options for a further $100 million in senior secured term loans — Term F and Term G — maturing in 2030.
What's the endgame? The money supports commercialization of Ardelyx's kidney-disease drugs, IBSRELA and XPHOZAH, and potential pipeline development. The company has favoured structured credit over dilutive equity to fund its growth.
What's the context? By April 2026, Ardelyx said it had refinanced its existing debt with SLR Investment Corp on better overall terms, aligning its balance sheet with rising drug revenue. The Term F draw extends SOFR-linked, interest-only debt out to 2030.
What could go wrong? Ardelyx still runs sizeable losses, posting a $37.6 million net loss in the first quarter of 2026. The new loan adds liquidity but also increases leverage and long-term obligations.
The signal: The $50 million draw ranks in the 95th percentile of debt rounds among biopharma companies in its market, out of 4,560 comparable deals. As more biopharma firms turn to term facilities and structured credit, the raise signals lender confidence in Ardelyx's cash-flow trajectory without diluting shareholders.
Read more: ainvest.com
